IFF outlines a Scent recovery driven by rebuilding R&D and go-to-market engines, plus a strategic shift toward higher-value natural ingredients, while navigating Middle East volatility. In 2H 2026, Fine Fragrance is projected softer in Q3 and stronger in Q4, and Consumer Fragrance should normalize to a low single-digit growth. The 2027 plan hinges on perfumer-led innovation, robust pipelines, and new delivery systems to win market share.
Generated by Dafinchi AI. Source-grounded AI analysis, not investment advice.
What are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
The excerpts point to three interconnected recovery drivers in the Scent businesses: (1) rebuilding the R&D and go-to-market engine, (2) portfolio/“product mix” shifts (notably higher-value natural products and compounds), and (3) active navigation of geopolitical volatility (Middle East) plus disciplined execution around comparables and productivity.
Management characterizes the R&D situation as having improved versus the prior baseline: the “R&D pipeline” was “not what it should have been” “2.5 years ago,” but now IFF says it has “a very strong R&D capability,” “great perfumers… developing absolutely leading-edge new Fine Fragrances and Consumer Fragrances,” and “a great pipeline of molecules as well as delivery systems.” 1
This matters because management frames Scent recovery as not just short-term demand stabilization, but rebuilding “the R&D capability [and] go-to-market approach with customers” to “drive market share gains.” 2
Management acknowledges “noise due to… the Middle East conflict on Fine Fragrances,” and also explains the recovery phasing: Fine Fragrance should be “a little bit softer in Q3, but a stronger Q4,” with a “mid-single-digit” trajectory on a second-half basis and “strong comparables.” 32
In addition, the Q2 outcome was helped by the team “manag[ing] the challenges in the Middle East,” with Fine Fragrance “finished up slightly positive” versus an expectation of “growth to be down in Fine Fragrance mid-single digits.” 4
For Consumer Fragrance, management says the business is expected to be in the “low single-digit range,” noting that while Q2 was “high single-digit,” it should “normalize… to kind of a low single-digit number.” 2
The recovery driver is still active: management highlights “rebuild the R&D capability go-to-market approach with customers” and “trying to drive market share gains” on the Consumer Fragrance side. 2
Even though your question focuses on Scent (Fine/Consumer Fragrance), IFF’s Scent segment performance in Q2 is described as being driven heavily by Fragrance Ingredients. Scent Q2 sales were up “8%,” with “Fragrance Ingredients… grew north of 20%,” with performance attributed partly to year-over-year delta (comparing to a “down 10% or more” prior period) and partly to leveraging the synthetics portfolio amid macro/supply disruptions and higher Brent crude. 4
Management also states that as things “settle down,” Fragrance Ingredients growth should “normalize… included in our forecast for the second half of the year,” shifting back toward “higher value-added ingredients versus the traditional synthetics.” 4
Management further clarifies that this shift “to higher-value natural products is underway” but “will take… more time,” with expectations that by “next year and the year after” IFF will have “a really strong competitive position.” 2
Scent profitability is described as improving: Scent segment EBITDA “growing 5% to $134 million,” with “Volume growth and productivity gains” as the primary drivers. 5
Below is the directly stated second-half evolution (rates described qualitatively in the transcript, but with ranges).
The excerpts describe R&D as both (a) a capability rebuild underway (pipeline, perfumers, molecules/delivery systems) and (b) linked to medium-term competitive positioning by “next year and the year after.”
Management states that today’s R&D setup includes:
Management explicitly connects R&D initiatives to go-to-market and market share:
While the question asks about R&D specifically, the excerpts also tie R&D-supported differentiation to the ingredient strategy:
Management says it is “really pleased with the progress” but “not satisfied… a lot more to do.” 1
This aligns with a continuing R&D roadmap that must both address existing gaps and keep strengthening pipeline output for the next competitive cycle(s) leading into/around 2027. 1
Disclaimer: The output generated by dafinchi.ai, a Large Language Model (LLM), may contain inaccuracies or "hallucinations." Users should independently verify the accuracy of any mathematical calculations, numerical data, and associated units, as well as the credibility of any sources cited. The developers and providers of dafinchi.ai cannot be held liable for any inaccuracies or decisions made based on the LLM's output.
IFF's Scent rebound hinges on stabilizing Fine Fragrance amid Middle East volatility, with Q3 softness and Q4 rebound, while Consumer Fragrance recovery relies on rebuilt R&D go-to-market capabilities and market-share gains. Fragrance Ingredients provide momentum that is expected to normalize in 2H, underpinning a stronger 2027 pipeline and competitive positioning.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF outlines a multi-year Scent recovery driven by stronger R&D, a rebuilt pipeline, and market-share gains, with near-term normalization across Fine Fragrance and Consumer Fragrance. In H2, Fine Fragrance is expected to improve toward a Q4 rebound, Consumer Fragrance normalizes to low single-digit growth, and sustained R&D investment is aimed at strengthening competitiveness into 2027.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF outlines a path for Scent’s recovery driven by a rebuilt R&D engine, an enhanced pipeline, and stronger go-to-market execution. In 2H 2026, Fine Fragrance is expected to soften in Q3 before a stronger Q4 with mid-single-digit growth, while Consumer Fragrance trends toward a low single-digit rate; Fragrance Ingredients momentum supports near-term results as R&D plans build toward 2027.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF outlines a Scent recovery anchored in disciplined reinvestment in R&D, a strengthened pipeline, and careful navigation of Middle East volatility, with 2H 2026 expected growth in Fine Fragrance and a normalization to low single digits in Consumer Fragrance. The multi-year R&D plan targets 2027 by advancing molecules, delivery systems, and leading‑edge perfumers to sustain competitive advantage.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF frames Scent's recovery around a rebuilt, stronger R&D pipeline and innovative delivery systems, with Fragrance Ingredients accelerating on higher-value inputs. For H2, Fine Fragrance should see a softer Q3 followed by a stronger Q4, while Consumer Fragrance is expected to grow in the low single digits as R&D and go-to-market efforts support market-share gains—backed by an ongoing 8-9% R&D investment to fuel 2027 growth.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF's Scent recovery hinges on a rebuilt R&D engine, stronger go-to-market execution, and resilient Fine Fragrance performance amid regional volatility. In H2, Fine Fragrance is expected to deliver mid-single-digit growth with a soft Q3 and stronger Q4, while Consumer Fragrance normalizes to low single-digit gains; the company reiterates a 2027-focused plan to sustain innovation through heightened R&D investment and a robust molecule and delivery-systems pipeline.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
Management outlines a disciplined capex path for Remainco, signaling capex around 5–6% of sales and R&D around 8–9% as a post-divestiture growth engine. They stress reinvestment to fuel innovation, margin expansion, and ongoing value creation, while noting near-term headwinds from the stand-alone transition.
Sources used
Research questionWhat did management say about Capex and reinvestment post-divestiture?
Answer outline
IFF's Scent segment posted an 8% Q2 sales rise led by double-digit growth in Fragrance Ingredients and a resilient Consumer Fragrance line, even as Fine Fragrance faced Middle East volatility. The firm outlines a two-track H2: mid-single-digit growth for Fine Fragrance with a Q3 soft patch and a rebound in Q4, while Consumer Fragrance normalizes after a standout Q2, underpinned by an R&D-driven push into 2027.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
Following the divestiture, IFF outlined a disciplined capex plan of 5-6% (tilting toward 6% over the next 1-2 years) and a sustained reinvestment cycle focused on R&D to differentiate the Remainco portfolio. The company also signaled stronger cash generation, projected deleveraging with net proceeds, and strategic cost management to support growth and margin expansion.
Sources used
Research questionWhat did management say about Capex and reinvestment post-divestiture?
Answer outline
IFF's Q2 2026 discussion frames a Scent recovery driven by a rebuilt R&D pipeline and stronger Consumer Fragrance execution, with Fine Fragrance set for Q4 recovery. The company emphasizes a longer-term R&D and ingredients strategy to support 2027 and beyond.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF’s Scent recovery is anchored in a rebuilt R&D engine, a stronger fragrance ingredients business, and a strategically paced turnaround for Fine and Consumer Fragrances in the second half of 2026. The discussion also highlights ongoing investments in a broader, more innovative product pipeline and a 2027 plan that relies on go-to-market rebuilds and sustained R&D spend to sustain growth and margin expansion.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF outlines that Scent’s rebound rests on a rebuilt R&D engine, a stronger pipeline, and improved go-to-market execution, with Fine Fragrance soft in Q3 and stronger in Q4, and Consumer Fragrance normalizing to low single-digit growth. The plan ties 2027 readiness to sustained R&D investment and closer customer collaboration, while Fragrance Ingredients normalization poses a near-term headwind before a shift to higher-value natural products strengthens longer-term competitiveness.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
Dafinchi